Richard Barry Buys 47,308 Shares of Cassava Sciences (NASDAQ:SAVA) Stock

Key Points

• Richard Barry, CEO of Cassava Sciences, purchased 47,308 shares of the company at an average cost of $2.29 per share, increasing his total ownership to 707,503 shares valued at approximately $1.62 million.
• The stock has experienced significant volatility, with a one-year low of $1.15 and a high of $33.98, and currently trades around $2.32 with a market cap of $112.07 million.
• Institutional investors collectively own 38.05% of Cassava Sciences, reflecting recent interest with multiple firms making new stakes in the company during the second quarter.

Cassava Sciences, Inc. (NASDAQ:SAVA - Get Free Report) CEO Richard Barry bought 47,308 shares of the business's stock in a transaction dated Friday, September 19th. The shares were bought at an average cost of $2.29 per share, for a total transaction of $108,335.32. Following the purchase, the chief executive officer directly owned 707,503 shares in the company, valued at approximately $1,620,181.87. This represents a 7.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Richard Barry also recently made the following trade(s):

• On Thursday, September 18th, Richard Barry acquired 190,633 shares of Cassava Sciences stock. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $427,017.92.

Cassava Sciences Price Performance

NASDAQ:SAVA traded up $0.04 during mid-day trading on Monday, hitting $2.32. 1,033,113 shares of the company's stock were exchanged, compared to its average volume of 1,327,459. Cassava Sciences, Inc. has a one year low of $1.15 and a one year high of $33.98. The business has a fifty day moving average price of $2.24 and a 200 day moving average price of $2.03. The company has a market cap of $112.07 million, a PE ratio of -0.91 and a beta of -2.06.

Cassava Sciences (NASDAQ:SAVA - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.18) EPS for the quarter. On average, equities analysts forecast that Cassava Sciences, Inc. will post -3.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. TT Capital Management LLC purchased a new stake in Cassava Sciences during the 2nd quarter valued at $28,000. Aristides Capital LLC bought a new position in Cassava Sciences in the second quarter valued at about $29,000. Ground Swell Capital LLC purchased a new stake in Cassava Sciences during the second quarter valued at approximately $31,000. Catalyst Funds Management Pty Ltd purchased a new stake in Cassava Sciences during the second quarter valued at approximately $34,000. Finally, Jump Financial LLC purchased a new stake in Cassava Sciences during the second quarter valued at approximately $50,000. Institutional investors own 38.05% of the company's stock.

About Cassava Sciences

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.